retatrutide trial results today Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Shows Promising Results in

But as its popularity grows, so do reports of serious gastrointestinal injuriesincluding bowel obstruction and ileus (intestinal paralysis)

While these products are often marketed as "wellness" breakthroughs, many have not been assessed for safety, efficacy, or quality, posing severe risks such as hormonal imbalances, liver damage, and infections

Ontdek nieuws en media-aandacht over afvallen, gezondheid en GLP-1

Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol use disorder

Proper storage of compounded semaglutide is critical to maintaining its effectiveness and safety

Here are 7 things to consider before you drink alcohol when youre on one of these drugs.